About
Sensible Medical Innovations has developed the ReDS medical radar technology, which originated from the defense industrys see through walls technology. ReDS is designed to monitor and manage patients with fluid management problems, including patients living with heart failure (HF), taking diuretic medication, or recovering from an event related to coronary artery disease. ReDS is intended for use by qualified healthcare practitioners and by patients under the direction of a physician in hospitals, hospital-type facilities, and the home environment. In a pilot study, ReDS-guided HF management reduced the number of HF-related rehospitalizations by approximately 80%. The company is headquartered in Israel with commercial offices in the United States. In August 2015, Sensible Medicals noninvasive thoracic fluid status monitor was cleared for market in the United States.
Funding history · 3 rounds · $37.6M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Sensible Medical Innovations' core technology?
- Sensible Medical Innovations has developed ReDS medical radar technology, which originated from defense industry 'see-through-walls' technology, designed for noninvasive lung fluid monitoring and management.
- When did Sensible Medical Innovations receive FDA clearance for its ReDS monitor?
- In August 2015, Sensible Medical Innovations' noninvasive thoracic fluid status monitor, ReDS, received FDA 510K clearance for market in the United States.
- What was the outcome of a pilot study using ReDS-guided heart failure management?
- A pilot study showed that ReDS-guided heart failure management reduced the number of HF-related rehospitalizations by approximately 80%.
- How much funding has Sensible Medical Innovations raised in total?
- Sensible Medical Innovations has raised a total of $37,561,000 across multiple funding rounds and grants.
- Which investors participated in Sensible Medical Innovations' Series A funding round?
- In June 2009, Sensible Medical Innovations raised $7,000,000 in a Series A round with participation from Vitalife and Genesis Partners.
- What was the most recent funding event for Sensible Medical Innovations?
- In January 2019, Medicure Inc. invested $10,000,000 in an Undisclosed Round to market Sensible Medical Innovations' ReDS technology.
- When did Sensible Medical Innovations license its ReDS technology to Bayer?
- In May 2019, Sensible Medical Innovations licensed its ReDS technology to Bayer.
- What significant market access did Sensible Medical Innovations achieve in September 2025?
- In September 2025, Sensible Medical Innovations' ReDS Pro System was contracted for inclusion in the Federal Supply Schedule (FSS), making it available for VA medical facilities in the US.
- How many employees does Sensible Medical Innovations currently have?
- Sensible Medical Innovations currently has 36 employees.